After Januvia And Onglyza, Novartis Launches Galvus In China; Lucentis Receives SFDA Nod
This article was originally published in PharmAsia News
Executive Summary
Novartis looks to take on Merck’s Januvia in China, noting it will have a level-playing field despite playing catch up in the market with the world’s largest diabetes population.